Transaction · 0001612842-26-000002

Wagner Paul A.

Wagner Paul A., SR, reported a transaction classified as withholding at Forte Biosciences, Inc. involving 164.000000 shares for an estimated $4472.28. Reported holdings after the transaction were 83178.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

withholdingSEC transaction code FSR
FBRXForte Biosciences, Inc.
Filing timeJan 02
Trade dateJan 01, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$23.61
Pre-filing
1mo ago -22.9%1w ago -22.9%1d ago -22.9%
Returns since
7d +0.0%30d +0.0%90d +5.3%180d -9.7%1y +225.9%

FBRX price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
FBRX since 2026-01-02Filed 244 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
withholding
Code F
Identifier
0001612842-26-000002
Common Stock
Transaction date
Jan 01, 2026
Filed Jan 02, 2026, 09:07 PM · 1d delay
Shares
164 sh
$2.72k per share
Estimated value
-$447k
Computed from shares × price
Holdings after
83.1k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership
-12score
Filing-only score

-12

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

SEE REMARKS

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.

  2. F2

    On January 1, 2026, the Reporting Person's RSUs vested. The closing price of the Issuer's Common Stock on December 31, 2025 was the settlement price used to calculate the shares withheld.

  3. F3

    Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to t…

Original filing · 0001612842-26-000002
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

FBRX